What is CommonQuant (Common Quant)?

CommonQuant, also written Common Quant, is an AI-powered trading platform that turns plain-English market ideas into live, rules-based strategies. It selects relevant instruments, writes indicator-based entry and exit rules, monitors the conditions continuously, and alerts users when conditions are met.

How does CommonQuant generate trading strategies?

You write a natural-language prompt describing your market idea. CommonQuant selects validated instruments, chooses from 20 supported technical indicators, and writes concrete entry and exit rules. The strategy then runs live and sends alerts through the channels available on your plan when conditions trigger.

What markets and instruments does CommonQuant support?

CommonQuant supports several thousand US equities and ETFs listed on Nasdaq, NYSE, NYSE American, and Cboe, plus major crypto assets such as Bitcoin. It does not support FX or futures.

How do I receive trading signal alerts?

CommonQuant provides an in-app signal inbox on all plans. Paid plans add email and Telegram, plus metered monthly SMS and WhatsApp allowances. Channel availability and allowances vary by plan.

Is CommonQuant free to use?

Yes. CommonQuant has a free tier with 1,000 starter credits, 200 monthly refill credits, up to three signal subscriptions, and in-app alerts. Paid plans start at $9/month, and no credit card is required to start.

Does CommonQuant provide financial advice?

No. CommonQuant is a quantitative tool for alpha validation and does not constitute financial advice. Past performance does not guarantee future results. Users are responsible for their own trading decisions.

Can I copy public trading strategies?

Yes. Users can browse, preview, and copy public community and AI-generated strategies into their own accounts. They can also follow strategists and take part in Arena competitions.

CommonQuant.ai Research

AI-generated trading idea · LONG · LLY

Eli Lilly's new weight-loss drug crushes trials — ride the breakout higher

Eli Lilly's stock is surging after the company announced highly successful late-stage trial results for its next-generation weight-loss drug, exciting analysts and reinforcing confidence in its portfolio.

Idea

Successful late-stage drug trials are massive catalysts for pharmaceutical companies because they essentially guarantee new, blockbuster revenue. With analysts highlighting that Lilly's portfolio is strong across the board rather than relying on just one drug, this new weight-loss data clears a major hurdle. As the company prepares to bring this drug to market, investor enthusiasm is likely to keep pushing the stock upward in the short term.

Key details

LLYD#pharma#earnings#momentum#breakout

Community

Upvotes

Views

Copies

Cosigns

News sources

Campbell's Earnings Beat; Eli Lilly Obesity Drug Results | Stock Movers — Bloomberg
Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug — MarketWatch

Eli Lilly's new weight-loss drug crushes trials — ride the breakout higher

Idea

Key details

Community

News sources

Related ideas

Related